Autolus Therapeutics plc
Status: Publicly traded
Direct answer
Autolus Therapeutics plc is publicly traded on NASDAQ under the ticker AUTL.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally,...
Can you invest in Autolus Therapeutics plc?
Yes. Autolus Therapeutics plc trades publicly on NASDAQ as AUTL.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Autolus Therapeutics plc
Detailed equity research is provided by MarketSnap.